Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

doi:10.3390/curroncol28060388

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34319

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34319

题名:	Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
作者:	Kang, Nai-Wen Tan, Kien-Thiam Li, Chien-Feng Kuo, Yu-Hsuan
贡献者:	Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol ACT Genom Co Ltd Chi Mei Med Ctr, Dept Med Res Natl Inst Canc Res, Natl Hlth Res Inst Chia Nan Univ, Coll Pharm & Sci
关键词:	neuroendocrine carcinoma immunotherapy immune checkpoint inhibitor tumor mutational burden
日期:	2021
上传时间:	2023-11-11 11:43:05 (UTC+8)
出版者:	MDPI
摘要:	Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment.
關聯:	CURR ONCOL, v.28, n.6, pp.4587-4596
显示于类别:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

文件中的档案:

档案	描述	大小	格式	浏览次数
curroncol28060388.pdf		3991Kb	Adobe PDF	209	检视/开启
index.html		0Kb	HTML	617	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....